FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044490503> ?p ?o ?g. }

• W2044490503 endingPage "1113.e1" @default.
• W2044490503 startingPage "1107" @default.
• W2044490503 abstract "BackgroundWe performed the first human case of successful transapical transcatheter aortic valve implantation on a beating heart in October 2005, and therefore we have the longest follow-up on transapical aortic valve implantation in humans. We now report clinical and echocardiographic outcomes of transapical aortic valve implantation in 71 patients.MethodsBetween October 2005 and February 2009, 71 patients (44 female) underwent transcatheter transapical aortic valve implantation with either 23- or 26-mm Edwards Lifesciences transcatheter bioprostheses. All patients with symptomatic aortic stenosis were declined for conventional aortic valve replacement owing to unacceptable operative risks and were not candidates for transfemoral aortic valve implantation because of poor arterial access. Clinical and echocardiographic follow-ups were performed before discharge, at 1 and 6 months, and then yearly. The mean follow-up was 12.9 ± 11.5 months with a total of 917.3 months of follow-up.ResultsMean age was 80.0 ± 8.1 years and predicted operative mortality was 34.5% ± 20.4% by logistic EuroSCORE and 12.1% ± 7.7% by The Society of Thoracic Surgeons Risk Calculator. Valves were successfully implanted in all patients. Twelve patients died within 30 days (30-day mortality: 16.9% in all patients, 33% in the first 15 patients, and 12.5% in the remainder), and 10 patients died subsequently. Overall survival at 24 and 36 months was 66.3% ± 6.4% and 58.0% ± 9.5%, respectively. Among 59 patients who survived at least 30 days, 24- and 36-month survivals were 79.8% ± 6.4% and 69.8% ± 10.9%, respectively. Late valve-related complications were rare. New York Heart Association functional class improved significantly from preoperative 3.3 ± 0.8 to 1.8 ± 0.8 at 24 months. The aortic valve area and mean gradient remained stable at 24 months (1.6 ± 0.3 cm2 and 10.3 ± 5.9 mm Hg, respectively).ConclusionOur outcome suggests that transapical transcatheter aortic valve implantation provides sustained clinical and hemodynamic benefits for up to 36 months in selected high-risk patients with symptomatic severe aortic stenosis. We performed the first human case of successful transapical transcatheter aortic valve implantation on a beating heart in October 2005, and therefore we have the longest follow-up on transapical aortic valve implantation in humans. We now report clinical and echocardiographic outcomes of transapical aortic valve implantation in 71 patients. Between October 2005 and February 2009, 71 patients (44 female) underwent transcatheter transapical aortic valve implantation with either 23- or 26-mm Edwards Lifesciences transcatheter bioprostheses. All patients with symptomatic aortic stenosis were declined for conventional aortic valve replacement owing to unacceptable operative risks and were not candidates for transfemoral aortic valve implantation because of poor arterial access. Clinical and echocardiographic follow-ups were performed before discharge, at 1 and 6 months, and then yearly. The mean follow-up was 12.9 ± 11.5 months with a total of 917.3 months of follow-up. Mean age was 80.0 ± 8.1 years and predicted operative mortality was 34.5% ± 20.4% by logistic EuroSCORE and 12.1% ± 7.7% by The Society of Thoracic Surgeons Risk Calculator. Valves were successfully implanted in all patients. Twelve patients died within 30 days (30-day mortality: 16.9% in all patients, 33% in the first 15 patients, and 12.5% in the remainder), and 10 patients died subsequently. Overall survival at 24 and 36 months was 66.3% ± 6.4% and 58.0% ± 9.5%, respectively. Among 59 patients who survived at least 30 days, 24- and 36-month survivals were 79.8% ± 6.4% and 69.8% ± 10.9%, respectively. Late valve-related complications were rare. New York Heart Association functional class improved significantly from preoperative 3.3 ± 0.8 to 1.8 ± 0.8 at 24 months. The aortic valve area and mean gradient remained stable at 24 months (1.6 ± 0.3 cm2 and 10.3 ± 5.9 mm Hg, respectively). Our outcome suggests that transapical transcatheter aortic valve implantation provides sustained clinical and hemodynamic benefits for up to 36 months in selected high-risk patients with symptomatic severe aortic stenosis." @default.
• W2044490503 created "2016-06-24" @default.
• W2044490503 creator A5001046803 @default.
• W2044490503 creator A5004557924 @default.
• W2044490503 creator A5005007989 @default.
• W2044490503 creator A5013679521 @default.
• W2044490503 creator A5027882695 @default.
• W2044490503 creator A5032700450 @default.
• W2044490503 creator A5032750069 @default.
• W2044490503 creator A5034137141 @default.
• W2044490503 creator A5040339119 @default.
• W2044490503 creator A5077926834 @default.
• W2044490503 creator A5084453617 @default.
• W2044490503 creator A5087291798 @default.
• W2044490503 date "2010-05-01" @default.
• W2044490503 modified "2023-10-16" @default.
• W2044490503 title "Transapical transcatheter aortic valve implantation: Follow-up to 3 years" @default.
• W2044490503 cites W180423479 @default.
• W2044490503 cites W1976669848 @default.
• W2044490503 cites W2007754522 @default.
• W2044490503 cites W2022017175 @default.
• W2044490503 cites W2032399758 @default.
• W2044490503 cites W2032400533 @default.
• W2044490503 cites W2049670131 @default.
• W2044490503 cites W2051862160 @default.
• W2044490503 cites W2059908491 @default.
• W2044490503 cites W2063777074 @default.
• W2044490503 cites W2072896674 @default.
• W2044490503 cites W2099772090 @default.
• W2044490503 cites W2111988269 @default.
• W2044490503 cites W2120508829 @default.
• W2044490503 cites W2124968972 @default.
• W2044490503 cites W2137307489 @default.
• W2044490503 cites W2148154533 @default.
• W2044490503 cites W2160820015 @default.
• W2044490503 cites W2167332311 @default.
• W2044490503 cites W3022029710 @default.
• W2044490503 doi "https://doi.org/10.1016/j.jtcvs.2009.10.056" @default.
• W2044490503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20412948" @default.
• W2044490503 hasPublicationYear "2010" @default.
• W2044490503 type Work @default.
• W2044490503 sameAs 2044490503 @default.
• W2044490503 citedByCount "114" @default.
• W2044490503 countsByYear W20444905032012 @default.
• W2044490503 countsByYear W20444905032013 @default.
• W2044490503 countsByYear W20444905032014 @default.
• W2044490503 countsByYear W20444905032015 @default.
• W2044490503 countsByYear W20444905032016 @default.
• W2044490503 countsByYear W20444905032017 @default.
• W2044490503 countsByYear W20444905032018 @default.
• W2044490503 countsByYear W20444905032020 @default.
• W2044490503 countsByYear W20444905032021 @default.
• W2044490503 crossrefType "journal-article" @default.
• W2044490503 hasAuthorship W2044490503A5001046803 @default.
• W2044490503 hasAuthorship W2044490503A5004557924 @default.
• W2044490503 hasAuthorship W2044490503A5005007989 @default.
• W2044490503 hasAuthorship W2044490503A5013679521 @default.
• W2044490503 hasAuthorship W2044490503A5027882695 @default.
• W2044490503 hasAuthorship W2044490503A5032700450 @default.
• W2044490503 hasAuthorship W2044490503A5032750069 @default.
• W2044490503 hasAuthorship W2044490503A5034137141 @default.
• W2044490503 hasAuthorship W2044490503A5040339119 @default.
• W2044490503 hasAuthorship W2044490503A5077926834 @default.
• W2044490503 hasAuthorship W2044490503A5084453617 @default.
• W2044490503 hasAuthorship W2044490503A5087291798 @default.
• W2044490503 hasBestOaLocation W20444905031 @default.
• W2044490503 hasConcept C126322002 @default.
• W2044490503 hasConcept C141071460 @default.
• W2044490503 hasConcept C164705383 @default.
• W2044490503 hasConcept C2776570981 @default.
• W2044490503 hasConcept C2777385415 @default.
• W2044490503 hasConcept C2780007028 @default.
• W2044490503 hasConcept C2780714102 @default.
• W2044490503 hasConcept C2781414266 @default.
• W2044490503 hasConcept C71924100 @default.
• W2044490503 hasConceptScore W2044490503C126322002 @default.
• W2044490503 hasConceptScore W2044490503C141071460 @default.
• W2044490503 hasConceptScore W2044490503C164705383 @default.
• W2044490503 hasConceptScore W2044490503C2776570981 @default.
• W2044490503 hasConceptScore W2044490503C2777385415 @default.
• W2044490503 hasConceptScore W2044490503C2780007028 @default.
• W2044490503 hasConceptScore W2044490503C2780714102 @default.
• W2044490503 hasConceptScore W2044490503C2781414266 @default.
• W2044490503 hasConceptScore W2044490503C71924100 @default.
• W2044490503 hasFunder F4320309139 @default.
• W2044490503 hasIssue "5" @default.
• W2044490503 hasLocation W20444905031 @default.
• W2044490503 hasLocation W20444905032 @default.
• W2044490503 hasOpenAccess W2044490503 @default.
• W2044490503 hasPrimaryLocation W20444905031 @default.
• W2044490503 hasRelatedWork W1979502020 @default.
• W2044490503 hasRelatedWork W1987049350 @default.
• W2044490503 hasRelatedWork W2003964523 @default.
• W2044490503 hasRelatedWork W2024496703 @default.
• W2044490503 hasRelatedWork W2067905792 @default.
• W2044490503 hasRelatedWork W2072807414 @default.
• W2044490503 hasRelatedWork W2550487528 @default.
• W2044490503 hasRelatedWork W2943312057 @default.

• next